A study was conducted in which a set of IL23mAb-PSMA-CAR was designed, and it was demonstrated in mice that IL-23 monoclonal antibody (IL-23mAb) combined with PSMA CAR was superior to PSMA CAR alone in eradicating prostate cancer (171). Here, FOLH1 is linked to prostate carcinoma.